Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Novartis posts eye drug data amid play for Eylea's turf

Reuters India Friday, 10 November 2017 ()
ZURICH (Reuters) - Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.
Share on
Share on
Post on 
Share by
Source: Wochit Business - < > Embed
News video: Novartis To Enter Eye-Drug Market

Novartis To Enter Eye-Drug Market 00:43

Novartis is gearing up to shake up a huge eye-drug market. Data presented Friday at the American Academy of Opthamology annual conference, revealed that drug company Novartis' drug brolucizumab was as comparable ot in some cases better than Eylea. Eylea is an existing drug to treat a condition called...

Recent related news

Molecular Health and U.S. Food and Drug Administration (FDA) Extend Software Collaboration to Drug Safety Prediction

** *Cambridge, MA, USA* - November 16, 2017 - * * Molecular Health, Inc (MH), a company marketing computational biomedicine tools to support healthcare...
GlobeNewswire - Press Releases

Using social media big data to combat prescription drug crisis

Researchers conducted a critical review of existing literature to determine whether social media big data can be used to understand communication and behavioral...
Science Daily - Science

You Might Like

Other recent news in Health

Health CANADA doesn't know if its dental programs benefiting Indigenous Canadians: reportAustralia's VICTORIA state closer to legalizing assisted death
David Cassidy, 'PARTRIDGE FAMILY' Star, Dies at 67Parents can help minimize CHILDREN's pain from vaccinations, study says
Opioid crisis cost U.S. economy $504 billion in 2015: WHITE HOUSEFrom 'Inky's Great Escape' To Singing Seahorses: Animal Books For The HOLIDAYS


Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+